High Quality Axitinib CAS 319460-85-0 Powder Fast Shipping Good Price

Axitinib More Info

Axitinib is a potent, highly selective, second-generation oral vascular endothelial growth factor 1. Compound Overview Axitinib is a potent, highly selective, second-generation oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. It exhibits targeted inhibitory activity against VEGFR-1, VEGFR-2, and VEGFR-3 at low picomolar to nanomolar concentrations. Compared with early multi-target tyrosine kinase inhibitors, this compound features superior kinase selectivity, with minimal off-target inhibition of other human kinases, which reduces non-specific toxic effects. It is widely applied in anti-tumor angiogenesis targeted therapy research and clinical treatment for malignant solid tumors. 2. Physical and Chemical Properties Axitinib is a white to pale yellow crystalline powder at room temperature. The compound presents extremely low aqueous solubility across the full physiological pH range (pH 1.1–7.8), classified as a poorly soluble BCS Class II drug. It is soluble in dimethyl sulfoxide and slightly soluble in other organic solvents. The molecule contains an E-type alkene double bond with no chiral structure, and it is non-hygroscopic under conventional storage conditions. The dissociation constant (pKa) is 4.8, and the lipid-water partition coefficient (logP) is approximately 3.5, indicating moderate lipophilicity suitable for oral absorption. Long-term stable storage requires low-temperature, light-proof and moisture-proof conditions. 3. Mechanism of Action The core pharmacological mechanism of axitinib is the competitive binding to the ATP-binding pocket of VEGFR intracellular kinase domains, thereby blocking VEGF-mediated signal transduction pathways. It effectively inhibits VEGF-induced vascular endothelial cell proliferation, migration, survival and increased vascular permeability. By suppressing pathological tumor angiogenesis, it reduces tumor microvascular density, blocks tumor nutrient and blood supply, and further inhibits tumor growth, invasion and distant metastasis. At therapeutic concentrations, axitinib shows negligible inhibitory effects on most other kinases, with only weak activity against PDGFR and c-Kit at elevated concentrations. Its high selectivity for VEGFR family kinases ensures targeted anti-angiogenic efficacy while lowering the incidence of multi-kinase inhibition-related adverse reactions. In combined therapy regimens with immune checkpoint inhibitors, axitinib can normalize abnormal tumor vasculature, improve tumor tissue perfusion and immune cell infiltration, and synergistically enhance anti-tumor immune efficacy. 4. Clinical Indications This compound is clinically indicated for the treatment of adult patients with advanced renal cell carcinoma. It is applicable for second-line monotherapy after failure of prior systemic anti-tumor therapy, and also serves as a core targeted drug for first-line combined immunotherapy regimens for advanced renal cell carcinoma. The safety and efficacy of axitinib in pediatric populations have not been fully verified, so it is not recommended for pediatric clinical use. 5. Pharmacokinetic Characteristics After oral administration in humans, axitinib is absorbed rapidly, with a peak plasma concentration reached 2.5 to 4 hours after dosing. Food intake has no significant impact on the overall systemic exposure of the compound. Hepatic metabolism is the primary elimination pathway, dominated by the CYP3A4/5 enzyme system, with minor metabolic pathways involving CYP1A2, CYP2C19 and UGT1A1. Strong CYP3A4 regulators can significantly alter the plasma concentration and metabolic clearance rate of axitinib, requiring dose adjustment or drug combination avoidance in clinical practice. The elimination half-life of axitinib ranges from 2.5 to 6.1 hours, supporting twice-daily oral administration to maintain stable effective blood drug concentration. Excretion is mainly through fecal and urinary pathways, and most metabolic products in vivo are pharmacologically inactive.

Product Image